Literature DB >> 3784284

Successful management of uric acid nephrolithiasis with potassium citrate.

C Y Pak, K Sakhaee, C Fuller.   

Abstract

Eighteen patients with uric acid nephrolithiasis (six with uric acid stones alone and 12 with both uric acid and calcium stones) underwent long-term treatment (1 to 5.33 years, mean of 2.78 years) with potassium citrate (30 to 80 mEq/day, usually 60 mEq/day). Urinary pH increased from low (5.30 +/- 0.31 SD) to normal (6.19 to 6.46) during treatment. Urinary content of undissociated uric acid, which was high to begin with at 204 +/- 82 mg/day, decreased to the normal range (64 to 108 mg/day) following treatment. Urinary citrate rose from 503 +/- 225 mg/day to 852 to 998 mg/day. Urinary saturation of calcium oxalate significantly declined with potassium citrate treatment. New stone formation rate declined from 1.20 +/- 1.68 stones/year to 0.01 +/- 0.04 stones/year (P less than 0.001 by chi square). Remission was experienced in 94.4% of patients, and the group stone formation rate declined by 99.2%. Detailed case reports were obtained in five patients showing different responses between sodium alkali and potassium alkali treatment. All five patients had persistently low urinary pH (typically less than 5.5) and normouricosuria, and four had hyperuricemia. Before treatment, they had stones surgically removed or spontaneously passed, which were pure uric acid in composition. When sodium alkali was give (as bicarbonate or citrate, 60 to 118 mEq/day), new stone formation continued in four patients, and a radiolucent (uric acid) calculus become "calcified" in the remaining patient. The stone analysis disclosed calcium oxalate in five patients and calcium phosphate in three patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3784284     DOI: 10.1038/ki.1986.201

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  32 in total

Review 1.  Nephrology: 1. Investigation and treatment of recurrent kidney stones.

Authors:  A Ross Morton; Eduard A Iliescu; James W L Wilson
Journal:  CMAJ       Date:  2002-01-22       Impact factor: 8.262

Review 2.  Pharmacotherapy of urolithiasis: evidence from clinical trials.

Authors:  Orson W Moe; Margaret S Pearle; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

3.  Evaluation and medical management of the kidney stone patient.

Authors:  Ryan Paterson; Alfonso Fernandez; Hassan Razvi; Roger Sutton
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

Review 4.  [Evidence-based pharmacological metaphylaxis of stone disease].

Authors:  M Straub; R E Hautmann
Journal:  Urologe A       Date:  2006-11       Impact factor: 0.639

5.  Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial.

Authors:  Shameez Allie-Hamdulay; Allen L Rodgers
Journal:  Urol Res       Date:  2005-05-04

6.  Update on the evaluation of repeated stone formers.

Authors:  Adam O Kadlec; Thomas M Turk
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

Review 7.  Prophylaxis of uric acid and cystine stones.

Authors:  B Hess
Journal:  Urol Res       Date:  1990

8.  Impact of Potassium Citrate vs Citric Acid on Urinary Stone Risk in Calcium Phosphate Stone Formers.

Authors:  Steeve Doizi; John R Poindexter; Margaret S Pearle; Francisco Blanco; Orson W Moe; Khashayar Sakhaee; Naim M Maalouf
Journal:  J Urol       Date:  2018-07-20       Impact factor: 7.450

Review 9.  Urolithiasis in children: current medical management.

Authors:  J Laufer; H Boichis
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

Review 10.  Urine citrate and renal stone disease.

Authors:  H Goldberg; L Grass; R Vogl; A Rapoport; D G Oreopoulos
Journal:  CMAJ       Date:  1989-08-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.